<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of antiphospholipid syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of antiphospholipid syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of antiphospholipid syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Doruk Erkan, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas L Ortel, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antiphospholipid syndrome (APS) is a clinical and laboratory diagnosis characterized by both persistent laboratory evidence of antiphospholipid antibodies (aPL) <strong>and</strong> related complications, which may include venous thrombosis, arterial thrombosis, adverse pregnancy outcomes, and nonthrombotic manifestations (eg, heart valve thickening, livedo reticularis/racemosa). APS occurs either as a primary condition or in the setting of an underlying disease, usually systemic lupus erythematosus (SLE).</p><p>The diagnosis and classification criteria for APS are reviewed here. It is important to note that:</p><p class="bulletIndent1"><span class="glyph">●</span>There are no diagnostic criteria for APS; therefore, the clinician’s assessment and judgment are critical for management decisions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2023 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) APS classification criteria have stringent definitions to allow more rigorous classification for research studies.</p><p></p><p>Additional topics discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Pathogenesis (see  <a class="medical medical_review" href="/z/d/html/4676.html" rel="external">"Pathogenesis of antiphospholipid syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations (see  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Management (see  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Obstetric implications (see  <a class="medical medical_review" href="/z/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis and treatment of catastrophic APS (see  <a class="medical medical_review" href="/z/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>The effect of aPL on coagulation tests (see  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Prolonged PT and/or aPTT without bleeding or thrombosis'</a>)</p><p></p><p class="headingAnchor" id="H450230226"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid syndrome</strong> – Antiphospholipid syndrome (APS) describes a clinical autoimmune syndrome characterized by one or more clinical manifestations (eg, venous thrombosis, arterial thrombosis, pregnancy morbidity, thrombocytopenia) with persistent laboratory evidence of antiphospholipid antibodies (aPL) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">APS can occur as a primary condition or in the setting of systemic lupus erythematosus (SLE) or another systemic autoimmune disease.</p><p></p><p class="bulletIndent1">APS can be further defined according to the type of clinical manifestation (some cases overlap) in each case with persistent laboratory criteria for aPL:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic APS</strong> – Thrombotic APS describes APS based on venous and/or arterial thrombosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Obstetric APS</strong> – Obstetric APS describes APS based on certain adverse pregnancy outcomes (eg, fetal death after 10 weeks gestation, premature birth due to severe preeclampsia or placental insufficiency, or multiple embryonic losses [before 10 weeks gestation]). (See <a class="local">'Classification criteria'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microvascular APS</strong> – Microvascular APS describes small vessel involvement, such as diffuse alveolar hemorrhage or aPL nephropathy, without moderate- to large-vessel thrombosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Catastrophic APS</strong> – Catastrophic APS (CAPS) is a rare, life-threatening form of APS characterized by thrombotic complications (macrovascular and microvascular) affecting multiple organs that develop simultaneously or over a short period of time. (See  <a class="medical medical_review" href="/z/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)"</a>.)</p><p></p><p class="bulletIndent1">Implications of these subgrouping for management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid antibodies</strong> – aPL are a heterogenous group of antibodies (immunoglobulins [Igs]) directed against phospholipids and phospholipid-binding proteins [<a href="#rid2">2</a>]. aPL can be transient (eg, associated with an acute infection) or persistent (present on two or more occasions at least 12 weeks apart).</p><p></p><p class="bulletIndent1">The commonly assayed aPL include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anticardiolipin antibody (aCL; IgG or IgM), assayed by enzyme-linked immunosorbent assay (ELISA)</p><p class="bulletIndent2"><span class="glyph">•</span>Anti-beta2 glycoprotein I antibody (anti-beta2GPI; IgG or IgM), assayed by ELISA</p><p class="bulletIndent2"><span class="glyph">•</span>Lupus anticoagulant (LA), assayed in a clotting test</p><p></p><p class="bulletIndent1">Although cardiolipin is a phospholipid, most of the clinically relevant antibodies detected in this assay actually bind to phospholipid-binding protein(s), frequently beta2GPI, that in turn bind to the cardiolipin. </p><p></p><p class="bulletIndent1">These three tests are also the ones included in the APS classification criteria. (See <a class="local">'Classification criteria'</a> below.)</p><p></p><p class="bulletIndent1">Other aPL are not routinely obtained or included in the classification criteria because of lack of standardized testing and/or uncertainty about their clinical significance (eg, IgA aCL and anti-beta2GPI or antibodies directed against prothrombin, phosphatidylserine, or phosphatidylinositol). (See <a class="local">'Antiphospholipid antibody testing'</a> below and  <a class="medical medical_review" href="/z/d/html/4676.html" rel="external">"Pathogenesis of antiphospholipid syndrome", section on 'Role of antiphospholipid antibodies'</a>.)</p><p></p><p class="headingAnchor" id="H389747"><span class="h1">WHEN TO SUSPECT THE DIAGNOSIS</span><span class="headingEndMark"> — </span>The two clinical scenarios that should raise clinical suspicion for antiphospholipid syndrome (APS) are:</p><p class="bulletIndent1"><span class="glyph">●</span>Otherwise unexplained thrombotic events (venous or arterial) or microvascular disease, especially in young patients (see  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Clinical manifestations'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Adverse outcomes related to pregnancy, especially associated with severe preeclampsia or placental insufficiency</p><p></p><p>If any of the above scenarios occurs in a patient who also manifests livedo reticularis/racemosa, valvular heart disease, pulmonary hemorrhage, thrombotic microangiopathy affecting the kidney, and/or neurologic findings such as cognitive deficits and white matter lesions, then the diagnostic suspicion for APS should be further increased.</p><p>The presence of a systemic autoimmune disease, especially systemic lupus erythematosus (SLE), should also increase the suspicion for APS in the setting of appropriate clinical symptoms.</p><p>Laboratory abnormalities that also raise suspicion for APS include otherwise unexplained thrombocytopenia, prolongation of the activated partial thromboplastin time (aPTT), or a history of a false-positive serologic test for syphilis (Venereal Disease Research Laboratory [VDRL] or rapid plasma reagin [RPR] tests). The VDRL and RPR tests use cardiolipin. (See  <a class="medical medical_review" href="/z/d/html/7588.html" rel="external">"Syphilis: Screening and diagnostic testing", section on 'Positive nontreponemal/negative treponemal'</a>.)</p><p>For patients with a low suspicion of APS, we generally do not test for antiphospholipid antibodies (aPL), such as older adults with venous thromboembolism (VTE) or stroke or individuals who have other risk factors for thromboembolism [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H72934381"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>In patients with suspected antiphospholipid syndrome (APS), we perform a thorough medical history, physical examination, and laboratory testing for antiphospholipid antibodies (aPL) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H60490084"><span class="h2">History</span><span class="headingEndMark"> — </span>The history should focus on:</p><p class="bulletIndent1"><span class="glyph">●</span>Nature and frequency of thrombotic events</p><p class="bulletIndent1"><span class="glyph">●</span>Outcomes of pregnancies</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Other risk factors for thrombosis (eg, immobility, use of estrogen-containing medications, family history of thrombophilia)</p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for other thrombotic syndromes (eg, history of heparin exposure raises the possibility of heparin-induced thrombocytopenia)</p><p class="bulletIndent1"><span class="glyph">●</span>Use of anticoagulants, which can affect the results of lupus anticoagulant (LA) testing (see <a class="local">'Patients on an anticoagulant'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms associated with systemic lupus erythematosus (SLE), such as arthritis/arthralgias, photosensitivity, oral ulcers, patchy hair loss, and Raynaud phenomenon (see  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'History and physical examination'</a>)</p><p></p><p class="headingAnchor" id="H60490091"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>There are no pathognomonic physical findings of APS; however, the examination may reveal findings related to ischemia or infarction of specific organs such as the skin or the central nervous system.</p><p>Examples of such physical findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>Livedo reticularis  (<a class="graphic graphic_picture graphicRef79545" href="/z/d/graphic/79545.html" rel="external">picture 1</a>) and particularly livedo racemosa  (<a class="graphic graphic_picture graphicRef139539" href="/z/d/graphic/139539.html" rel="external">picture 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Digital ischemia or gangrene</p><p class="bulletIndent1"><span class="glyph">●</span>Sequelae of deep vein thrombosis (leg edema, skin changes)</p><p class="bulletIndent1"><span class="glyph">●</span>A heart murmur</p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic abnormalities suggestive of a prior stroke</p><p></p><p>Clinical findings are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>.)</p><p class="headingAnchor" id="H2187626790"><span class="h2">Laboratory evaluation</span></p><p class="headingAnchor" id="H1873264592"><span class="h3">Routine laboratory testing</span><span class="headingEndMark"> — </span>We perform the following initial laboratory tests in all patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count</strong> – Thrombocytopenia may be observed in patients with APS. (See  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Thrombocytopenia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baseline coagulation testing</strong> – The prothrombin time (PT) and activated partial thromboplastin time (aPTT) are important prior to starting anticoagulation, especially if they will be used for monitoring. Testing for lupus anticoagulant is discussed below. (See <a class="local">'Specific antiphospholipid antibody tests'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum creatinine and urinalysis with urine sediment</strong> – A serum creatinine and urinalysis with urine sediment may help identify kidney involvement; abnormal findings may also suggest a concomitant or alternative diagnosis (eg, SLE). Patients with abnormal kidney function, microscopic hematuria, proteinuria, or an active urinary sediment will need further evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SLE testing</strong> – Patients with clinical features suggestive of SLE should also undergo the appropriate clinical evaluation for SLE. In a cohort of 1000 individuals with APS, 36 percent had SLE, and an additional 5 percent had a lupus-like syndrome [<a href="#rid5">5</a>]. Further testing is not required unless clinical features of SLE are identified. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'</a>.)</p><p></p><p class="headingAnchor" id="H60490098"><span class="h3">Antiphospholipid antibody testing</span></p><p class="headingAnchor" id="H3994195892"><span class="h4">Specific antiphospholipid antibody tests</span><span class="headingEndMark"> — </span>Antibody testing in patients with suspected APS involves two immunoassays and a functional coagulation assay  (<a class="graphic graphic_algorithm graphicRef140013" href="/z/d/graphic/140013.html" rel="external">algorithm 1</a>) [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anticardiolipin antibodies (aCL); IgG and IgM by enzyme-linked immunosorbent assay (ELISA).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-beta2 glycoprotein I antibodies (anti-beta2GPI); IgG and IgM by ELISA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LA functional coagulation assay, which is a three-step procedure:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Demonstration of a prolonged phospholipid-dependent screening test of hemostasis. Commonly used screening tests include the dilute Russell viper venom time (dRVVT) or an aPTT that has been optimized for LA testing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mixing patient plasma with normal plasma fails to correct the prolonged screening test(s). This finding documents the presence of an inhibitor, rather than a coagulation factor deficiency.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Addition of excess phospholipid shortens or corrects the prolonged coagulation test. This finding demonstrates phospholipid dependence.</p><p></p><p class="bulletIndent1">A positive LA is characterized by correction of the prolonged clotting time with added phospholipid but not with control plasma, confirming that the coagulation inhibitor is phospholipid dependent [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Lupus anticoagulant tests'</a> and  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Use of mixing studies'</a>.)</p><p></p><p>The above aPL testing is consistent with recommendations from the International Society on Thrombosis and Haemostasis for laboratory criteria in APS [<a href="#rid7">7</a>].</p><p>Clinical relevance of different antibody isotypes (IgG versus IgM versus IgA) is discussed below.</p><p>We do <strong>not</strong> routinely perform laboratory testing for other antibodies such as antibodies against antiprothrombin, annexin V, phosphatidylserine, and phosphatidylinositol, given the lack of standardized testing and uncertainty about their clinical significance [<a href="#rid8">8</a>].</p><p>In addition, we generally do not test for the IgA isotypes when evaluating for APS, and we generally do not consider these antibodies as supportive evidence for the diagnosis of APS if they are reported. In contrast to IgG and IgM isotypes of aCL and anti-beta2GPI, the association of the IgA isotypes with clinical thrombosis remains controversial [<a href="#rid9">9</a>]. Very limited data indicate that medium to high levels of IgA aCL and/or IgA anti-beta2GPI may be associated with APS, although in our experience, this is extremely rare. However, many laboratories routinely test for IgA isotype aCL and anti-beta2GPI, given that rarely patients present with persistent isolated moderate- to high-titer IgA aCL or anti-beta2GPI in the setting of aPL-related clinical events.</p><p>The Laboratory Diagnostics and Trends APS Task Force of the 14<sup>th</sup> International Congress on aPL concluded that the evidence to include IgA isotype as part of the APS Classification Criteria is only of low quality; furthermore, since IgA aPL are usually associated with aPL of other isotypes, it can be difficult to understand the role of IgA alone [<a href="#rid8">8</a>]. Thus, the utility of testing for IgA isotype is generally restricted to those patients with a strong clinical suspicion for APS who have tested negative for other tests for aPL [<a href="#rid10">10</a>]. Additional prospective studies are needed to better understand the role of IgA aCL antibody as a risk factor for thrombosis.</p><p>The Systemic Lupus International Collaborating Clinics (SLICC) revised classification criteria for SLE  (<a class="graphic graphic_table graphicRef86633" href="/z/d/graphic/86633.html" rel="external">table 1</a>) include IgA isotype of aCL and anti-beta2GPI as part of the definition of aPL positivity; IgA isotype may have implications for SLE classification given that it is more common in SLE patients compared with aPL-positive patients without other autoimmune diseases [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Classification criteria'</a>.)</p><p>Some clinical laboratories use automated chemiluminescence tests instead of ELISA-based assays for the detection of aCL and anti-beta2GPI. Chemiluminescence assays generally have higher analytical sensitivities (they can detect lower levels of antibodies) than ELISA assays. The units and "cut-off" values used in these chemiluminescence-based tests are not equivalent to the ELISA units and cutoff values.</p><p class="headingAnchor" id="H614382228"><span class="h4">Timing of testing</span><span class="headingEndMark"> — </span>Initial testing is usually done shortly after a clinical event, followed by confirmatory testing at least 12 weeks later.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial aPL testing</strong> – Typically, initial aPL testing is performed at the time of the thrombosis or adverse pregnancy outcome. While we obtain all of the tests listed above (see <a class="local">'Specific antiphospholipid antibody tests'</a> above), it is worth noting that an acute thrombotic event may falsely normalize the aPTT. Thus, a normal aPTT or other LA screening test in the acute setting may be inaccurate and may need to be repeated. The immunoassays (ELISAs for aCL or beta2GPI) are not affected by acute thrombotic events or anticoagulants. (See <a class="local">'Patients on an anticoagulant'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirmatory aPL testing</strong> – In patients with initial positive testing for aPL, testing should be repeated after ≥12 weeks to confirm persistence of the aCL, anti-beta2GPI, or LA. Transiently elevated levels of IgG or IgM aCL, as well as a positive LA test, can occur with certain infections or drug exposures. (See <a class="local">'Other conditions associated with antiphospholipid antibodies'</a> below.)</p><p></p><p>For the majority of patients who do not have laboratory evidence of APS, we do not perform additional antibody testing. However, repeat testing may be appropriate in selected cases in which the clinical suspicion for APS is especially high.</p><p>The need for confirmatory testing due to the possibility of transient aPL positivity was illustrated in a study including randomly selected blood donors who were tested for the presence of aCL and LA [<a href="#rid12">12</a>]. On initial testing, 28 of 503 (5.6 percent) were positive for IgG aCL, 38 of 457 (8.3 percent) were positive for IgM aCL, and an additional 5 (0.9 percent) were positive for both. The number who remained positive for aCL upon repeat testing declined progressively at 3, 6, 9, and 12 months; at one year, only four (0.8 percent) were positive for IgG aCL, one (0.2 percent) for IgM aCL, and none for both isotypes. There were no positive tests for LA in any patient, and none of the individuals had clinical evidence of APS.</p><p class="headingAnchor" id="H172884294"><span class="h4">Patients on an anticoagulant</span><span class="headingEndMark"> — </span>In patients who are receiving an anticoagulant, we test for aCL and anti-beta2GPI antibodies; these results are unaffected by anticoagulation. By contrast, different anticoagulants have variable effects on laboratory tests used to identify LA, making interpretation of the results more challenging  (<a class="graphic graphic_table graphicRef91267" href="/z/d/graphic/91267.html" rel="external">table 2</a>). Communication with the consulting specialist and laboratory personnel is advised prior to LA testing in a patient receiving an anticoagulant. This subject is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Patient on anticoagulant'</a>.)</p><p class="headingAnchor" id="H5609732"><span class="h4">Interpretation of positive results</span></p><p class="headingAnchor" id="H3074990574"><span class="h5">Clinically relevant antiphospholipid antibody profile</span><span class="headingEndMark"> — </span>Not every positive aPL test result is clinically relevant. The interpretation of "clinically relevant aPL positivity" should take into account the type of assay, isotype, titer or level, persistence, and number of positive aPL tests.</p><p>We define a clinically relevant aPL profile as the persistent presence of one or more of the following aPL on two or more occasions at least 12 weeks apart:</p><p class="bulletIndent1"><span class="glyph">●</span>Positive LA test, based on the guidelines of International Society of Thrombosis and Haemostasis [<a href="#rid13">13</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>aCL IgG or IgM, with a titer &gt;40 units</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-beta2GPI IgG or IgM, with a titer &gt;40 units</p><p></p><p>[<a href="#rid14">14-16</a>]</p><p>The clinical significance of IgA aCL and IgA anti-beta2GPI are not clear and are addressed above. (See <a class="local">'Specific antiphospholipid antibody tests'</a> above.)</p><p class="headingAnchor" id="H1951659008"><span class="h5">Risk stratification based on antiphospholipid antibody profile</span><span class="headingEndMark"> — </span>Patients with clinically relevant aPL profiles may be further stratified into high-, moderate-, and low-risk profiles:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk profile</strong> – A persistently positive LA with or without persistently positive moderate- to high-titer aCL and/or anti-beta2GPI IgG or IgM (moderate titer 40 to 79 units, high titer ≥80 units). (See <a class="local">'Clinically relevant antiphospholipid antibody profile'</a> above.)</p><p></p><p class="bulletIndent1">Some experts consider triple-positive results (LA, aCL, and anti-beta2GPI) to be associated with the highest risk for clinical complications.</p><p></p><p class="bulletIndent1">Implications of high-risk aPL profiles are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Risk of a first thrombosis with aPL'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate-risk profile</strong> – A negative LA test with persistently positive moderate- to high-titer aCL and/or anti-beta2GPI IgG or IgM (moderate titer 40 to 79 units, high titer ≥80 units).</p><p></p><p class="bulletIndent1">The IgG isotype of aCL and anti-beta2GPI has a stronger association with aPL-related clinical events compared with IgM isotypes [<a href="#rid14">14-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk profile</strong> – A negative LA test with persistently positive low-titer aCL and/or anti-beta2GPI IgG or IgM (low titer 20 to 39 units).</p><p></p><p class="bulletIndent1">There are insufficient data regarding the clinical significance of aCL or anti-beta2GPI IgG or IgM titers that are above the upper limit of the reference range for the test but &lt;40 units.</p><p></p><p>Transient or persistent aPL may also be present in other settings besides APS and is discussed further below. (See <a class="local">'Other conditions associated with antiphospholipid antibodies'</a> below.)</p><p class="headingAnchor" id="H178994"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of antiphospholipid syndrome (APS) is based on the presence of at least one clinical manifestation (venous thrombosis, arterial thrombosis, pregnancy morbidity) in the setting of persistently positive antiphospholipid antibodies (aPL)  (<a class="graphic graphic_algorithm graphicRef140013" href="/z/d/graphic/140013.html" rel="external">algorithm 1</a>). Laboratory testing must be positive on two separate occasions at least 12 weeks apart to confirm persistence. (See <a class="local">'Antiphospholipid antibody testing'</a> above.)</p><p>Although the diagnosis of APS is based on a combination of clinical features and positive aPL, three major factors that should be carefully assessed for APS diagnosis are:</p><p class="bulletIndent1"><span class="glyph">●</span>The strength of the association between the clinical event and aPL</p><p class="bulletIndent1"><span class="glyph">●</span>Other risk factors associated with the clinical event</p><p class="bulletIndent1"><span class="glyph">●</span>The aPL profile</p><p></p><p>In patients with thrombosis and/or pregnancy morbidity (especially in those with late fetal loss because of eclampsia, preeclampsia, or placental insufficiency), the confidence in the diagnosis of APS increases when any of the following apply:</p><p class="bulletIndent1"><span class="glyph">●</span>Two or more clinically relevant and persistent aPL laboratory results are present. (See <a class="local">'Clinically relevant antiphospholipid antibody profile'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The anticardiolipin antibodies (aCL) and/or anti-beta2 glycoprotein I (anti-beta2GPI) are IgG rather than isolated IgM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional aPL-related manifestations are present, such as otherwise unexplained thrombocytopenia, heart valve disease, or thrombotic microangiopathy affecting the kidney (aPL nephropathy) [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alternative explanations for the thrombosis or pregnancy morbidity are lacking.</p><p></p><p>When needed, consultation with an APS expert is advised.</p><p class="headingAnchor" id="H15"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of antiphospholipid syndrome (APS) is broad and includes other causes of arterial and venous thrombosis and recurrent pregnancy loss. It is also important to note that antiphospholipid antibodies (aPL) may overlap with other conditions that can cause thrombosis or pregnancy morbidity.</p><p class="headingAnchor" id="H2160960287"><span class="h2">Other causes of thrombosis</span><span class="headingEndMark"> — </span>Other causes of thrombosis include inherited and acquired thrombophilias, anatomic vascular obstruction, paroxysmal nocturnal hemoglobinuria, heparin-induced thrombocytopenia, and myeloproliferative neoplasms (MPNs). Vaccine-induced immune thrombotic thrombocytopenia (VITT) is an exceedingly rare condition seen following vaccination with an adenoviral vector-based coronavirus disease 2019 (COVID-19) vaccine. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a> and  <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">"Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"</a> and  <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">"Clinical presentation and diagnosis of heparin-induced thrombocytopenia"</a> and  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a> and  <a class="medical medical_review" href="/z/d/html/131333.html" rel="external">"COVID-19: Vaccine-induced immune thrombotic thrombocytopenia (VITT)"</a>.)</p><p>Like APS, these conditions may be associated with arterial or venous thromboembolism, with or without cytopenias. Unlike APS, these conditions are not associated with laboratory evidence of persistent aPL.</p><p>Patients with APS may also have coexisting risk factors for thrombotic events, including immobility, use of estrogen-containing medications, and/or cardiovascular risk factors. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H4092793078"><span class="h2">Other causes of pregnancy morbidity</span><span class="headingEndMark"> — </span>Other causes of recurrent pregnancy loss include chromosomal abnormalities, anatomical abnormalities of the uterus, and endocrine disorders such as hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/5436.html" rel="external">"Recurrent pregnancy loss: Evaluation"</a>.)</p><p>Like APS, individuals with these abnormalities may have early or late pregnancy loss. Unlike APS, these conditions generally are not associated with an increased risk of thromboembolism or the presence of aPL.</p><p class="headingAnchor" id="H4063492555"><span class="h2">Positive antiphospholipid antibodies without antiphospholipid syndrome</span></p><p class="headingAnchor" id="H1962611196"><span class="h3">Transient antiphospholipid antibodies</span><span class="headingEndMark"> — </span>The incidence and clinical significance of transient aPL in the absence of clinical thrombosis or other features of APS is unclear. For selected individuals who have incidentally identified aPL without APS, follow-up testing to assess the persistence of an aPL may be helpful.</p><p>The clinical impact of repeat testing in asymptomatic individuals with aPL depends on how the results will be incorporated into patient management. For patients with multiple strongly positive tests, repeat testing provides information about potential risk assessment; by contrast, for patients with a single borderline positive test, repeat testing can be used to confirm that the result is likely to be clinically irrelevant.</p><p class="headingAnchor" id="H4114688592"><span class="h3">Persistent lupus anticoagulant or medium-/high-titer anticardiolipin antibody/anti-beta2 glycoprotein I IgG/IgM</span><span class="headingEndMark"> — </span>Occasionally, individuals are identified who have a high- or moderate-risk aPL profile but no clinical manifestations of APS. (See <a class="local">'Risk stratification based on antiphospholipid antibody profile'</a> above.)</p><p>The two most common scenarios in which this occurs are patients with systemic lupus erythematosus (SLE) who are routinely screened for aPL and patients undergoing coagulation screening for an unrelated indication who are found to have a lupus anticoagulant (LA).</p><p>While these patients do not have APS by classification or diagnostic criteria, they are at risk for aPL-related clinical manifestations as noted above.</p><p>It is reasonable to assume that all patients with APS were, for some period of time in the past, asymptomatic individuals with significant levels of aPL. The level of risk and the role of prophylaxis in such patients is controversial and discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Primary thrombosis prevention'</a>.)</p><p class="headingAnchor" id="H763875928"><span class="h3">Other conditions associated with antiphospholipid antibodies</span><span class="headingEndMark"> — </span>In addition to their occurrence in primary APS, aPL may be present in some people who are otherwise healthy, have an autoimmune or rheumatic disease, and/or have been exposed to certain drugs or infectious agents.</p><p>The presence of aPL alone, in the absence of a thrombotic event or pregnancy morbidity, is insufficient for diagnosis of the clinical syndrome of APS. (See <a class="local">'Diagnosis'</a> above.)</p><p>The evaluation of a patient with a positive aPL for autoimmune and infectious conditions depends on the presentation and clinical setting. In general, we limit our evaluation to a thorough history and physical examination and testing appropriate to evaluate clinical findings. We do not perform antinuclear antibody (ANA) testing or other studies to evaluate for these conditions in the absence of other clinical findings suggestive of an autoimmune or infectious disorder. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune and rheumatic diseases</strong> – The most frequent rheumatic disease associated with aPL is SLE. A clinically significant aPL profile in the absence of APS has been detected in approximately 30 percent of patients with SLE [<a href="#rid18">18</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately 31 percent of patients have LA [<a href="#rid19">19</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>23 to 47 percent have an anticardiolipin antibody (aCL) [<a href="#rid9">9,19,20</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>20 percent have antibodies to beta2 glycoprotein I (beta2GPI) [<a href="#rid9">9</a>]</p><p></p><p class="bulletIndent1">Conversely, in a cohort of 1000 APS patients, APS was associated with SLE in 36 percent of patients and with a lupus-like syndrome in an additional 5 percent [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Both LA and aCL have also been found in patients with a variety of other autoimmune and rheumatic diseases (eg, scleroderma, psoriatic arthritis), but in the absence of clinical events associated with the APS, their significance is not clear [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – aPL have also been noted in patients with infections. These are usually low-level IgM aCL, which may rarely result in thrombotic events [<a href="#rid21">21,23</a>]. Furthermore, these antibodies usually are not beta2GPI dependent; thus, patients with infections usually do not express antibodies to beta2GPI [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent1">Infections that have been associated with aPL include [<a href="#rid22">22,24-32</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bacterial</strong> – Bacterial sepsis, leptospirosis, syphilis, Lyme disease (borreliosis), tuberculosis, leprosy, infective endocarditis, post-streptococcal rheumatic fever, and Klebsiella infections.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Viral</strong> – Hepatitis A and B; mumps; human immunodeficiency virus (HIV); human T-lymphotropic virus type 1 (HTLV-I); cytomegalovirus; varicella-zoster; Epstein-Barr virus (EBV); adenovirus; parvovirus; rubella; and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.</p><p></p><p class="bulletIndent2">Additional information regarding COVID-19 and the presence of aPL can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4676.html" rel="external">"Pathogenesis of antiphospholipid syndrome", section on 'COVID-19 and antiphospholipid antibodies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parasitic</strong> – Malaria, <em>Pneumocystis jirovecii</em>, and visceral leishmaniasis (also known as kala-azar).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – A number of medications have been associated with aPL. These include phenothiazines (<a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">chlorpromazine</a>), <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a>, <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>, alpha interferon, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="9248" href="/z/d/drug information/9248.html" rel="external">chlorothiazide</a>, oral contraceptives, and <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid22">22,23,33,34</a>].</p><p></p><p class="bulletIndent1">The aPL are usually transient, often of the IgM isotype, and rarely associated with thrombosis. The mechanism of drug-induced aPL is not known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – aPL have been detected in patients with solid tumors (lung, colon, cervix, prostate, kidney, ovary, breast, and bone); Hodgkin disease and non-Hodgkin lymphoma; MPNs (primary myelofibrosis, polycythemia vera); and myeloid and lymphocytic leukemias [<a href="#rid22">22,35</a>].</p><p></p><p class="headingAnchor" id="H3137674416"><span class="h1">CLASSIFICATION CRITERIA</span><span class="headingEndMark"> — </span>Classification criteria for antiphospholipid syndrome (APS) were developed to define a patient population for clinical and laboratory research studies [<a href="#rid36">36,37</a>]. Consequently, these criteria emphasize specificity over sensitivity, meaning that some patients may have a clinical diagnosis of APS without meeting classification criteria. As an example, a patient who meets laboratory criteria and has a venous thromboembolism (VTE) or macrovascular arterial thrombosis would not meet classification criteria for APS if they have a high-risk profile for VTE or cardiovascular disease. Similarly, patients who meet clinical criteria but who only have anticardiolipin antibody (aCL) or anti-beta2 glycoprotein I (beta2GPI) IgM without IgG or lupus anticoagulant (LA) would not meet classification criteria. Thus, while the underlying principles of the classification criteria can be useful to guide diagnosis and document key disease features, use of these criteria should not substitute for clinical judgment when diagnosing APS [<a href="#rid38">38,39</a>]. (See <a class="local">'Diagnosis'</a> above.)</p><p>The American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) released updated classification criteria in 2023 [<a href="#rid40">40</a>]; they include definitions of clinical and laboratory criteria  (<a class="graphic graphic_table graphicRef142726" href="/z/d/graphic/142726.html" rel="external">table 3</a>), definitions of high-risk profiles for VTE and cardiovascular disease  (<a class="graphic graphic_table graphicRef142727" href="/z/d/graphic/142727.html" rel="external">table 4</a>), and a graphic describing a scoring system  (<a class="graphic graphic_figure graphicRef142725" href="/z/d/graphic/142725.html" rel="external">figure 1</a>). Patients who fulfill entry criteria and who have at least three weighted criteria in both the clinical and laboratory domains meet the classification criteria for APS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entry criteria</strong> – Patients must fulfill at least one documented clinical criterion below and have a positive antiphospholipid antibody (aPL) test within three years of the clinical criterion (defined as a positive LA or a moderate to high titer of IgG or IgM aCL or anti-beta2GPI).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical criteria</strong> – Patients must meet three or more weighted criteria, with possible clinical manifestations including the following  (<a class="graphic graphic_figure graphicRef142725" href="/z/d/graphic/142725.html" rel="external">figure 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Macrovascular venous thromboembolism</strong> – An otherwise unexplained VTE including but not limited to pulmonary embolism, deep vein thrombosis of the arms or legs, and thrombosis of the splanchnic veinous system, renal vein, cerebral venous system, or retinal vein. VTE must be confirmed by appropriate testing (eg, imaging or pathology). Superficial venous thrombosis does <strong>not</strong> satisfy this criterion. Criterion weighting depends on whether patients have a high-risk profile for VTE (eg, active malignancy, recent surgery, or major trauma)  (<a class="graphic graphic_table graphicRef142727" href="/z/d/graphic/142727.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Macrovascular arterial thrombosis</strong> – An otherwise unexplained arterial thrombosis including but not limited to myocardial infarction, stroke, thromboses of the peripheral, splanchnic, or retinal arteries, and organ infarcts without visualized thrombus (eg, kidney, liver, spleen). Arterial thrombosis or organ infarct must be confirmed by appropriate testing (eg, imaging or pathology). Weighting depends on whether patients have a high-risk profile for cardiovascular disease (eg, hypertension, hyperlipidemia)  (<a class="graphic graphic_table graphicRef142727" href="/z/d/graphic/142727.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microvascular manifestations</strong> – These include suspected or established livedo racemosa or livedoid vasculopathy, aPL nephropathy, pulmonary or adrenal hemorrhage, and myocardial disease. Weighting depends on whether diagnosis is suspected or established (eg, examination versus pathology for livedoid vasculopathy). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy morbidity</strong> – These include three or more consecutive pre-fetal (&lt;10 weeks gestation) or early fetal (10 to 15 weeks gestation) deaths, fetal death (16 to 33 weeks gestation) in the absence of severe preeclampsia or placental insufficiency, and severe preeclampsia or/or placental insufficiency before 34 weeks gestation with or without fetal death. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac valve abnormalities</strong> – These include types of valve thickening and vegetations as outlined in the table  (<a class="graphic graphic_table graphicRef142726" href="/z/d/graphic/142726.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematologic abnormalities</strong> – This includes thrombocytopenia (20 to 130 x 10<sup>9</sup>/L) confirmed on peripheral smear and repeat testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory criteria</strong> – Patients must meet three or more weighted laboratory criteria. Persistence (two positive tests at least 12 weeks apart) is required for aCL and anti-beta2GPI, and part of the weighting for LA. Laboratory criteria include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LA detected according to published guidelines [<a href="#rid3">3,41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive IgM aCL and/or anti-beta2GPI in moderate or high titer (moderate titer 40 to 79 units, high titer ≥80 units measured by a standardized enzyme-linked immunosorbent assay [ELISA] according to recommended procedures) [<a href="#rid6">6,42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive IgG aCL and/or anti-beta2GPI in moderate or high titer (moderate titer 40 to 79 units, high titer ≥80 units measured by a standardized ELISA according to recommended procedures) [<a href="#rid6">6,42</a>]. Weighting depends on whether it is moderate or high titer and whether one or both antibodies are present.</p><p></p><p>Prior classification criteria for APS include the revised Sapporo APS classification criteria (also called the Sydney criteria)  (<a class="graphic graphic_table graphicRef104569" href="/z/d/graphic/104569.html" rel="external">table 5</a>) [<a href="#rid36">36</a>]. When compared with these criteria, the 2023 ACR/EULAR criteria have higher specificity and lower sensitivity (specificity 99 percent versus 86 percent, sensitivity of 84 percent versus 99 percent) [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H225882851"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111936.html" rel="external">"Society guideline links: Antiphospholipid syndrome"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/575.html" rel="external">"Patient education: Antiphospholipid syndrome (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Clinical suspicion for antiphospholipid syndrome (APS) should be raised in either of the following settings (see <a class="local">'When to suspect the diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic events</strong> – One or more otherwise unexplained venous or arterial thromboses/thromboemboli, especially in young patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse pregnancy outcomes</strong> – One or more specific adverse pregnancy outcomes, including multiple embryonic losses &lt;10 weeks gestation, fetal death after 10 weeks gestation, or premature birth due to severe preeclampsia or placental insufficiency.</p><p></p><p class="bulletIndent1">Clinical suspicion is further increased if either of these occur in a patient with livedo reticularis/racemosa; valvular heart disease; neurologic findings (eg, cognitive deficits and white matter lesions); or a systemic autoimmune disease, especially systemic lupus erythematosus (SLE).</p><p></p><p class="bulletIndent1">Laboratory abnormalities suggestive of APS include unexplained mild thrombocytopenia, increased activated partial thromboplastin time (aPTT), or false-positive serologic test for syphilis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – In patients with suspected APS, we perform a thorough medical history, physical examination, complete blood count, and testing for antiphospholipid antibodies (aPL). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1">We generally perform initial testing around the time of a clinical event, followed by confirmatory testing ≥12 weeks later (see <a class="local">'Timing of testing'</a> above). We test for three aPL (see <a class="local">'Specific antiphospholipid antibody tests'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>aCL</strong> – Anticardiolipin antibodies (aCL); IgG and IgM, by enzyme-linked immunosorbent assay (ELISA)</p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anti-beta2GPI</strong> – Anti-beta2 glycoprotein I (anti-beta2GPI) antibodies; IgG and IgM, by ELISA</p><p class="bulletIndent2"><span class="glyph">•</span><strong>LA</strong> – Lupus anticoagulant (LA), using a functional clotting assay (see  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Lupus anticoagulant tests'</a>)</p><p></p><p class="bulletIndent1">It may be appropriate to pursue additional laboratory testing or to evaluate patients for other possible causes of thromboembolism and/or adverse pregnancy outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of APS is based on a combination of clinical features (venous or arterial thromboembolism or certain pregnancy morbidities) and the aPL profile (persistently positive clinically relevant aPL)  (<a class="graphic graphic_algorithm graphicRef140013" href="/z/d/graphic/140013.html" rel="external">algorithm 1</a>). Risk factors for thrombosis other than APS should also be evaluated during the diagnostic assessment. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential</strong> <strong>diagnosis</strong> – The differential diagnosis of APS includes other causes of arterial and venous thrombosis and recurrent pregnancy loss. aPL may also be present in other conditions (autoimmune or rheumatic disease, malignancy, infection, medications). In some individuals with aPL, an associated condition is not identified. (See <a class="local">'Other causes of thrombosis'</a> above and <a class="local">'Other causes of pregnancy morbidity'</a> above and <a class="local">'Other conditions associated with antiphospholipid antibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification criteria</strong> – APS classification criteria  (<a class="graphic graphic_table graphicRef142726" href="/z/d/graphic/142726.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef142727" href="/z/d/graphic/142727.html" rel="external">table 4</a> and <a class="graphic graphic_figure graphicRef142725" href="/z/d/graphic/142725.html" rel="external">figure 1</a>) were designed for research purposes and can be useful to help guide clinical diagnosis, but they should not substitute for clinical judgment when diagnosing APS. Specifically, classification criteria alone should not be used to exclude the diagnosis of APS in patients with clinical manifestations and laboratory findings consistent with the APS diagnosis. (See <a class="local">'Classification criteria'</a> above.)</p><p></p><p class="headingAnchor" id="H445260"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter Schur, MD, and Bonnie Bermas, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018; 378:2010.</a></li><li class="breakAll">Khamashta MA, Amigo MC. Antiphospholipid syndorme: overview of pathogenesis, diagnosis, and management. In: Rheumatology, 6, Hochberg MC, Silman AJ, Smolen JS, et al (Eds), Elsevier, 2015. Vol 2, p.1144.</li><li><a class="nounderline abstract_t">Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7:1737.</a></li><li><a class="nounderline abstract_t">Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376:1498.</a></li><li><a class="nounderline abstract_t">Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019.</a></li><li><a class="nounderline abstract_t">Giannakopoulos B, Passam F, Ioannou Y, Krilis SA. How we diagnose the antiphospholipid syndrome. Blood 2009; 113:985.</a></li><li><a class="nounderline abstract_t">Devreese KMJ, Ortel TL, Pengo V, et al. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16:809.</a></li><li><a class="nounderline abstract_t">Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014; 13:917.</a></li><li><a class="nounderline abstract_t">Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999; 28:344.</a></li><li class="breakAll">Bertolaccini ML, Amengual O, Artim-Eser B, et al. Clinical and prognostic significance of non-criteria antiphospholipid antibody tests. In: Antiphospholipid Syndrome: Current Research Highlights and Clinical Insights, Erkan D, Lockshin MD (Eds), Springer International Publishing, 2017. p.171.</li><li><a class="nounderline abstract_t">Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.</a></li><li><a class="nounderline abstract_t">Vila P, Hernández MC, López-Fernández MF, Batlle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72:209.</a></li><li><a class="nounderline abstract_t">Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18:2828.</a></li><li><a class="nounderline abstract_t">Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost 2016; 14:1530.</a></li><li><a class="nounderline abstract_t">Chayoua W, Kelchtermans H, Gris JC, et al. The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost 2020; 18:169.</a></li><li><a class="nounderline abstract_t">Erkan D. Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. Arthritis Rheumatol 2021; 73:1780.</a></li><li><a class="nounderline abstract_t">Abreu MM, Danowski A, Wahl DG, et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14:401.</a></li><li><a class="nounderline abstract_t">Taraborelli M, Leuenberger L, Lazzaroni MG, et al. The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus 2016; 25:1365.</a></li><li><a class="nounderline abstract_t">Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682.</a></li><li><a class="nounderline abstract_t">Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99:624.</a></li><li><a class="nounderline abstract_t">McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193.</a></li><li><a class="nounderline abstract_t">Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology 2003; 207:5.</a></li><li><a class="nounderline abstract_t">Triplett DA. Many faces of lupus anticoagulants. Lupus 1998; 7 Suppl 2:S18.</a></li><li><a class="nounderline abstract_t">McNally T, Purdy G, Mackie IJ, et al. The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91:471.</a></li><li><a class="nounderline abstract_t">Santiago M, Martinelli R, Ko A, et al. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol 2001; 19:425.</a></li><li><a class="nounderline abstract_t">García Moncó JC, Wheeler CM, Benach JL, et al. Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides. J Neurol Sci 1993; 117:206.</a></li><li><a class="nounderline abstract_t">Prieto J, Yuste JR, Beloqui O, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996; 23:199.</a></li><li><a class="nounderline abstract_t">Matsuda J, Saitoh N, Gotoh M, et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995; 90:1138.</a></li><li><a class="nounderline abstract_t">Leroy V, Arvieux J, Jacob MC, et al. Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C. Br J Haematol 1998; 101:468.</a></li><li><a class="nounderline abstract_t">Muñoz-Rodríguez FJ, Tàssies D, Font J, et al. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol 1999; 30:770.</a></li><li><a class="nounderline abstract_t">Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31:256.</a></li><li><a class="nounderline abstract_t">Von Landenberg P, Lehmann HW, Knöll A, et al. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003; 48:1939.</a></li><li><a class="nounderline abstract_t">Merrill JT, Shen C, Gugnani M, et al. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24:1083.</a></li><li><a class="nounderline abstract_t">Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep 2012; 14:71.</a></li><li><a class="nounderline abstract_t">Vassalo J, Spector N, de Meis E, et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care 2014; 29:533.</a></li><li><a class="nounderline abstract_t">Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295.</a></li><li><a class="nounderline abstract_t">Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309.</a></li><li><a class="nounderline abstract_t">Kaul M, Erkan D, Sammaritano L, Lockshin MD. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007; 66:927.</a></li><li><a class="nounderline abstract_t">Bobba RS, Johnson SR, Davis AM. A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value? J Rheumatol 2007; 34:1522.</a></li><li><a class="nounderline abstract_t">Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol 2023; 75:1687.</a></li><li class="breakAll">Ledford-Kraemer M, Moore GW, Bottenus R, et al. Laboratory testing for the lupus anticoagulant; approved guideline. CLSI document H60-A. Clinical and Laboratory Standards Institute 2014. https://clsi.org/media/1386/h60a_sample.pdf (Accessed on July 17, 2023).</li><li><a class="nounderline abstract_t">Reber G, Tincani A, Sanmarco M, et al. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2:1860.</a></li></ol></div><div id="topicVersionRevision">Topic 4678 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791828" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Management of the Antiphospholipid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791828" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and Management of the Antiphospholipid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624461" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20822807" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953980" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18755986" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : How we diagnose the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29532986" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24824074" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665739" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665739" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22553077" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7831653" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33462974" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27279342" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31519058" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The (non-)sense of detecting anti-cardiolipin and anti-β2glycoprotein I IgM antibodies in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114366" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25641203" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26945023" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110431" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7503085" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853785" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunology and clinical importance of antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638896" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and epidemiological aspects in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9814666" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Many faces of lupus anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8547096" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The use of an anti-beta 2-glycoprotein-I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11491498" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410057" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8591841" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611213" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633888" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10365800" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836658" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Viral infections and antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847688" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195513" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High prevalence of antiphospholipid antibodies in patients taking procainamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160568" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Drug-induced lupus anticoagulants and antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629573" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16420554" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403256" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17337473" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Assessment of the 2006 revised antiphospholipid syndrome classification criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17552042" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37635643" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37635643" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15456509" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
